Affimed N.V. announced that two abstracts with its innate cell engager (ICE(R)) AFM24 have been accepted for the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place June 2 - 6, 2023 in Chicago, IL. Leveraging innate immunity with AFM24, a novel CD16A and epidermal growth factor receptor (EGFR) bispecific innate cell engager: Interim results for the non-small cell lung cancer (NSCLC) cohort. Leveraging innate immunity withAFM24, a novel CD 16A and epidermal growth factors receptor (EGFR) bis pecific innate cell engager: interim results for the non- small cell lung cancer (NSCL CRC) cohort.